ribosomal protein L10 pseudogene 2Genealiases: RPL10_2_670 · RPL10p · bA209A2.1
Q-omics provides the consensus-scored RPL10P2 profile across patient tissues and cancer cell-line models. RPL10P2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RPL10P2 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, RPL10P2 RNA expression shows 6,793 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, HNSC, and STAD as cancer lineages where RPL10P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL10P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL10P2 survival associations across molecular data types. RPL10P2 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL10P2 RNA expression–survival associations across cancer types. High RPL10P2 expression shows unfavorable associations in KIRC, but favorable associations in MESO, BRCA, HNSC, ACC and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify MESO as the clearest survival context for RPL10P2 RNA expression.
This table summarizes RPL10P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL10P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL10P2 shows lower tumor expression in ESCA and KICH and higher tumor expression in HNSC, LUAD, KIRC and LIHC. The HNSC box plot shows higher RPL10P2 RNA expression in tumor versus normal tissue (log2 FC = +0.088, t-test p = .012).
This table shows molecular features associated with RPL10P2 in patient tissues and cancer cell lines. In patient samples, RPL10P2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
